Lo mejor del 2020: estudios que marcarán nuestra práctica clínica

Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China of novel coronavirus-infected pneumonia. N Engl J Med 2020;382: 1199–207. https://doi.org/10.1056/nejmoa2001316

Coronavirus resource center. Disponible en: COVID-19 Map - Johns Hopkins Coronavirus Resource Center (jhu.edu). Acceso 25 de diciembre, 2020.

Organización mundial de la salud, enfermedades cardiovasculares. Cardiovascular diseases (who.int). Acceso 25 de diciembre, 2020.

Tromp J, Bamadhaj S, Cleland J, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 2020 Mar;8(3): e411-e422. https://doi.org/10.1016/s2214-109x(20)30004-8

Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with Empaglifozin in Heart Failure. N Engl J Med 2020 Oct 8;383(15):1413-24. https://doi.org/10.1056/nejmoa2022190

Packer M, Anker S, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. https://doi.org/10.1161/circulationaha.120.051783

Armstrong P, Pieske B, Anstrom K, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020 May 14;382(20):1883-93. https://doi.org/10.1056/nejmoa1915928

Teerlink J, Diaz R, Felker G, et al. Cardiac Myosin activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2020 Nov 13. doi: 10.1056/NEJMoa2025797.

Heerspink H, Stefansson B, Correa‑Rotter R, et al. Dapaglifozin in patients with Chronic Kidney disease. N Engl J Med 2020 Oct 8;383(15):1436-46. https://doi.org/10.1056/nejmoa2024816

Bhatt D, Szarek M, Steg P, et al. Sotaglifozin in patients with Diabetes and recent Worsening Heart Failure. N Engl J Med 2020 Nov 16. https://doi.org/10.1056/nejmoa2030183

Bhatt D, Szarek M, Pitt B, et al. Sotaglifozin in patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2020 Nov 16. https://doi.org/10.1056/nejmoa2030186

Anthony A. Bavry. Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction – PARALLAX. Disponible en: Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction - American College of Cardiology (acc.org). Acceso 25 de diciembre 2020.

Solomon S, McMurray J, Anand I, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019 Oct 24;381(17):1609-20. https://doi.org/10.1056/nejmoa1908655

FDA Briefing Document. NDA 207620 Sacubitril/Valsartan. Disponible en: download (fda.gov). Acceso 25 de diciembre 2020.

Klip I, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575–82.e3. https://doi.org/10.1016/j.ahj.2013.01.017

Ponikowski P, Kirwan B, Anker S, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020 Dec 12;396(10266):1895-904. https://doi.org/10.1016/s0140-6736(20)32339-4

Dangas G, Baber U, Sharma S, et al. Ticagrelor with aspirin or alone after complex PCI: the TWILIGHT-COMPLEX analysis. J Am Coll Cardiol 2020;75:2414–24. https://doi.org/10.1016/j.jacc.2020.03.011

Angiolillo D, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J Am Coll Cardiol 2020;75:2403–13. https://doi.org/10.1016/j.jacc.2020.03.008

Kim B, Hong S, Cho Y, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020 Jun 16;323(23):2407-16. https://doi.org/10.1001/jama.2020.7580

Tardif J, Kouz S, Waters D, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019 Dec 26;381(26):2497-505. https://doi.org/10.1056/nejmoa1912388

Bouabdallaoui N, Tardif J, Waters D, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020 Nov 7;41(42):4092-99. https://doi.org/10.1093/eurheartj/ehaa659

Bavry A. Colchicine Cardiovascular Outcomes Trial – COLCOT. Disponible en: Colchicine Cardiovascular Outcomes Trial - American College of Cardiology (acc.org). Acceso 25 de diciembre 2020.

Nidorf S, Fiolet A, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020 Nov 5;383(19):1838-47. https://doi.org/10.1056/nejmoa2021372

Deepak L, Bhatt P, Steg G, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019 Jan 3;380(1):11-22. https://doi.org/10.1056/nejmoa1812792

Budoff M, Bhatt D, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J 2020 Oct 21;41(40):3925-32. https://doi.org/10.1093/cvr/cvaa184

Borja, I. Stefan, J. et al. (2017). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 00, 1-66. https://doi.org/10.1093/eurheartj/ehx393

Collet J, Thiele H, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020 Aug 29; ehaa575. doi:10.1093/eurheartj/ehaa57

Steg P. Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia – REALITY. Disponible en: Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia - American College of Cardiology (acc.org). Acceso: 25 de diciembre 2020.

Carson J. Myocardial Ischemia and Transfusion (MINT). Disponible en: Myocardial Ischemia and Transfusion - Full Text View - ClinicalTrials.gov. Acceso: 25 de diciembre 2020.

Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020 Sep 12;396(10253):759-69. https://doi.org/10.1016/s0140-6736(20)31792-x

Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696–707. https://doi.org/10.1056/nejmoa1915152

Nijenhuis V, Brouwer J, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020 Oct 8;383(15):1447-57. https://doi.org/10.1056/nejmoa2017815

Basel Ramlawi. Evolut Low Risk Bicuspid Study: Favorable Safety with TAVR in Patients with Bicuspid Valve. Disponible en: Evolut Low Risk Bicuspid Study: Favorable Safety with TAVR in Patients with Bicuspid Valve - American College of Cardiology (acc.org). Acceso: 25 de diciembre 2020.

Guimaraes H, Lopes R, de Barros P, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med 2020 Nov 26;383(22):2117-26. https://doi.org/10.1056/nejmoa2029603